Application of vanillyl alcohol in preparation of medicine for preventing and treating fatty liver, obesity or diabetes

Abstract

The invention discloses application of vanillyl alcohol in preparation of medicines for preventing and treating fatty liver, obesity or diabetes, and belongs to the technical field of medicines. The invention is implemented in vitro and in vivo, and aims to solve the problem of lack of low-toxicity natural small molecule drugs for effectively preventing and treating fatty liver, obesity or diabetes at present. The embodiment of the invention proves that the vanillyl alcohol can obviously reduce high-fat diet induced mouse fat deposition, reduce in-vivo and in-vitro liver TG content and lipid droplet accumulation, enhance glucose tolerance of the high-fat diet induced mouse and improve insulin resistance of the high-fat diet induced mouse. As a natural antioxidant, vanillyl alcohol has an obvious relieving effect on energy metabolism disorder and oxidative stress induced by high fat. As a low-toxicity natural small molecule, vanillyl alcohol can improve glucose and lipid metabolism disorder induced by high fat, is low in price, and has application value in preparation of medicines for preventing and treating fatty liver, obesity or diabetes mellitus.

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to the use of vanillyl alcohol (VA) in the preparation of medicines for preventing and treating fatty liver, obesity or diabetes. Background Art

[0002] Fatty liver disease, obesity, and diabetes are increasingly common metabolic diseases worldwide and have become a major public health issue. With changes in modern lifestyles, particularly shifts in diet and decreased physical activity, the incidence of these diseases has increased annually and is closely associated with a variety of serious complications.

[0003] Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a condition characterized by liver fat accumulation and is often associated with metabolic problems such as obesity, diabetes, and hyperlipidemia. Excessive liver fat accumulation in MAFLD can cause liver inflammation, liver cell damage, and liver fibrosis, ultimately progressing to non-alcoholic steatohepatitis (MASH), cirrhosis, and even liver cancer. The global prevalence of MAFLD has reached 25%, and with the increasing prevalence of obesity and diabetes, the incidence of MAFLD is increasing annually.

[0004] Obesity is a chronic metabolic disease caused by excessive energy intake and insufficient energy expenditure, primarily manifested by excessive fat accumulation. Obesity is not only a significant risk factor for cardiovascular disease, diabetes, and metabolic syndrome, but is also closely associated with liver fat accumulation, making it a key pathogenic factor in MAFLD. Obesity further increases the risk of other metabolic diseases by triggering inflammatory responses and insulin resistance.

[0005] Diabetes, particularly type 2 diabetes mellitus (T2DM), is a highly prevalent metabolic disease worldwide. It is primarily caused by insufficient insulin secretion or impaired insulin action, leading to elevated blood sugar levels. The onset of T2DM is closely linked to obesity, genetics, environmental factors, and lifestyle, and is often accompanied by complications such as cardiovascular disease and kidney disease. Obesity, particularly visceral fat accumulation, is a major risk factor for T2DM.

[0006] While progress has been made in the treatment of fatty liver disease, obesity, and diabetes, many challenges remain. In particular, fatty liver disease relies primarily on lifestyle interventions, and there is a lack of effective medications to prevent its progression from simple fat accumulation to MASH or cirrhosis. Furthermore, the treatment of obesity and diabetes is still hampered by drug side effects, and existing therapies have limited effectiveness. Therefore, there is an urgent need to identify innovative drugs that can prevent and alleviate fatty liver disease, obesity, and diabetes. In recent years, a growing number of studies have demonstrated that natural small molecule compounds have good efficacy and a high safety profile in alleviating MAFLD. Therefore, the search for new drugs from natural small molecules to treat fatty liver disease, obesity, and diabetes holds great promise.

[0007] Vanillyl alcohol is a phenolic compound found in a variety of plants and has attracted considerable attention due to its unique aroma and wide range of applications. It is widely used in various foods, cosmetics, and pharmaceuticals.

[0008] So far, there is no report in the prior art about the use of vanillyl alcohol in the preparation of drugs for treating fatty liver, obesity and diabetes, nor is there any similar suggestion or attempt. Summary of the Invention

[0009] The present invention aims to provide a method for preparing a drug for preventing and treating fatty liver, obesity or diabetes. The present invention aims to solve the current problem of the lack of low-toxicity natural small molecule drugs that can effectively prevent and treat fatty liver, obesity or diabetes.

[0010] The purpose of the present invention is achieved through the following technical solutions:

[0011] The present invention comprises the following steps: (1) establishing an in vitro lipid accumulation model of HepG2 cells induced by oleic acid / palmitic acid; (2) intervening in the induced cell model by adding vanillyl alcohol to the culture medium; (3) detecting various cell-related indicators; (4) establishing an in vivo high-fat diet-induced obesity model and non-alcoholic fatty liver disease model in mice; (5) intraperitoneally injecting vanillyl alcohol into the mice to intervening in the induced model; and (6) tracking various physiological indicators of the mice and conducting lipid metabolism-related studies on the mouse body weight and liver. The experiments verify the use of vanillyl alcohol in the preparation of drugs for the prevention and treatment of fatty liver, obesity, or diabetes.

[0012] In vitro studies have shown that vanillyl alcohol has no significant effect on hepatocyte viability at concentrations below 100 μM, suggesting potential for pharmaceutical applications. Further studies have revealed that the addition of vanillyl alcohol at concentrations between 50 μM and 100 μM can reduce triglyceride levels in HepG2 human liver cancer cells. Vanillyl alcohol also promotes cellular energy metabolism by increasing ATP levels and mitochondrial number in HepG2 cells. Vanillyl alcohol also exerts antioxidant capacity by reducing MDA and ROS levels and increasing GSH, CAT, and SOD levels in HepG2 cells. Furthermore, vanillyl alcohol can inhibit the expression of lipid synthesis genes such as ACC1 and FASN, while promoting the expression of lipid degradation genes such as PPARα and PGC1α. These findings suggest that vanillyl alcohol can alleviate lipid metabolism disorders in HepG2 cells, regulate intracellular energy metabolism, and mitigate high-fat-induced oxidative stress.

[0013] In vivo studies have shown that vanillyl alcohol can alleviate obesity induced by a high-fat diet and reduce triglyceride accumulation in the livers of mice fed a high-fat diet. Vanillyl alcohol also improves glucose tolerance and insulin sensitivity in mice fed a high-fat diet. In summary, vanillyl alcohol can improve glucose and lipid metabolism disorders, alleviate the development of obesity, fatty liver disease, and diabetes, and improve the symptoms of obesity, fatty liver disease, and diabetes.

[0014] The results of in vitro and in vivo tests in the examples of the present invention show that vanillyl alcohol can be used in the preparation of drugs for preventing and treating fatty liver, obesity or diabetes.

[0015] The prevention and treatment include one or more of prevention, alleviation or treatment.

[0016] The fatty liver is metabolism-related fatty liver disease.

[0017] The diabetes is type 2 diabetes.

[0018] The prepared medicine for preventing and treating fatty liver, obesity or diabetes is an injectable preparation or an oral medicine.

[0019] The injection preparation drug is one of an injection liquid preparation, a freeze-dried powder injection, an emulsion preparation, a sustained-release preparation or a microcapsule preparation.

[0020] The injection preparation further contains pharmaceutically acceptable excipients and / or carriers. The excipients and / or carriers are one or more of saline, sterile water, Ringer's solution, buffered saline, glucose solution, maltodextrin solution, glycerol, ethanol, lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0021] The amount of the vanillyl alcohol used is 200 mg / kg-400 mg / kg, preferably 200 mg / kg.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The present invention found that vanillyl alcohol can alleviate obesity induced by a high-fat diet and reduce the accumulation of triglycerides in the liver of mice fed a high-fat diet. Vanillyl alcohol improved glucose tolerance and insulin sensitivity in mice induced by a high-fat diet. In summary, vanillyl alcohol can improve glucose and lipid metabolism disorders and alleviate the occurrence of fatty liver, obesity, and diabetes. Therefore, it is confirmed that vanillyl alcohol can be used in the preparation of drugs for the prevention and treatment of fatty liver, obesity, or diabetes; and vanillyl alcohol does not produce toxic side effects such as changes in cell activity. Therefore, a low-toxic natural small molecule drug - vanillyl alcohol - is provided for the effective prevention or treatment of fatty liver, obesity, or diabetes. Compared with the high-cost fat-reducing drugs currently available on the market, vanillyl alcohol has better natural biological activity, a wide source, low price, and is extremely easy to obtain, with broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 The figure shows the effect of different concentrations of VA on the activity of HepG2 human liver cancer cells.

[0025] Figure 2 The graph shows the results of TG content detection in HepG2 human liver cancer cells after treatment with different concentrations of VA.

[0026] Figure 3 This is the Oil Red O staining result of HepG2 human liver cancer cells after VA treatment.

[0027] Figure 4 This is the result of detecting the mRNA levels of HepG2 human liver cancer cells related genes after VA treatment.

[0028] Figure 5 This is the result of mitochondrial staining detection of HepG2 human liver cancer cells after VA treatment.

[0029] Figure 6 This figure shows the results of mtDNA level detection in HepG2 human liver cancer cells after VA treatment.

[0030] Figure 7 This figure shows the detection results of mitochondrial ATP levels in HepG2 human liver cancer cells after VA treatment.

[0031] Figure 8 This figure shows the results of ROS level detection in HepG2 human liver cancer cells after VA treatment.

[0032] Figure 9 This is the result of MDA level detection in HepG2 human liver cancer cells after VA treatment.

[0033] Figure 10 This is the result of detecting GSH, SOD and CAT levels in HepG2 human liver cancer cells after VA treatment.

[0034] Figure 11 The graph shows the results of body weight and body fat percentage testing of mice after high-fat diet and VA treatment.

[0035] Figure 12 The results of CT detection of fat distribution in mice after high-fat diet and VA treatment.

[0036] Figure 13 Photos of adipose tissue of mice after high-fat diet and VA treatment, and the results of adipose tissue weight / body weight are shown.

[0037] Figure 14 Photographs of the livers of mice after high-fat diet and VA treatment.

[0038] Figure 15 Schematic diagram of TG and Oil Red O staining results of mice after high-fat diet and VA treatment.

[0039] Figure 16 This is a graph showing the glucose tolerance (GTT) test and the area under the glucose tolerance curve of mice after high-fat diet and VA treatment.

[0040] Figure 17 The results of the insulin sensitivity (ITT) test and the area under the insulin tolerance curve of mice after high-fat diet and VA treatment. DETAILED DESCRIPTION

[0041] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making any creative efforts shall fall within the scope of protection of the present invention.

[0042] Currently, there is a lack of low-toxic natural small molecule drugs that can effectively alleviate liver steatosis. In order to solve the above technical problems, the present invention proposes the use of vanillyl alcohol in the preparation of drugs for preventing and treating fatty liver, obesity or diabetes.

[0043] Example 1

[0044] Technical Solution: This example investigates the regulatory effects of vanillyl alcohol (VA) on hepatic lipid metabolism disorders using both in vitro and in vivo experiments, utilizing an oleic acid / palmitic acid-induced HepG2 cell fat accumulation model and a high-fat diet-induced C57BL / 6J mouse obesity model. In vitro experiments: HepG2 cells were passaged and cultured in DMEM supplemented with fetal bovine serum for 24 hours. The fat accumulation model was induced using oleic acid / palmitic acid, and VA was added to the cells for 24 hours. A control without VA was used to investigate the effects of varying concentrations of vanillyl alcohol on lipid accumulation, energy metabolism, and oxidative stress. In vivo study: Twenty-four 8-week-old C57BL / 6 mice were randomly divided into four groups (n=6 per group): (1) CON: control diet (10% Kcal fat); (2) HFD: high-fat diet (60% Kcal fat); (3) HFD+VA-L: high-fat diet treated with low-concentration VA (60% Kcal fat, 200 mg / kg VA / body weight); and (4) HFD+VA-H: high-concentration VA treated with high-fat diet (60% Kcal fat, 400 mg / kg VA / body weight). VA was administered via intraperitoneal injection twice a week. The experimental period lasted for 12 weeks. The temperature of the environment was 25±2°C, the relative humidity was 50±5%, and the mice were kept in an alternating pattern of 12 hours of light and 12 hours of darkness using an incandescent lamp. Water and food were available freely. After the end of the feeding period, the mice were sacrificed and tissue samples were collected to observe the effects of vanillyl alcohol treatment on liver lipid metabolism, fat deposition, and glucose metabolism.

[0045] (I) The details of the in vitro experiments are as follows:

[0046] 1. Detection of the effect of vanillyl alcohol on HepG2 cell activity

[0047] The cells were seeded into 96-well plates and incubated in an incubator for 24 h. They were then treated with 0, 10, 25, 50, 75, and 100 μM VA for 24 h. Cell Counting Kit-8 (Solerbo) was used to incubate the cells for 1 h to detect cell viability and the effect of vanillin on hepatocyte activity.

[0048] 2. Detection of the Effect of Vanillyl Alcohol on Lipid Metabolism in HepG2 Cells

[0049] The cell samples of the OA / PA group and the OA / PA+VA treatment group were tested for changes in intracellular and extracellular TG and TC using a triglyceride test kit and a total cholesterol test kit (Nanjing Jiancheng). The cells with different treatments were stained with Oil Red O to observe the intracellular lipid accumulation, and the changes in the mRNA levels of lipid metabolism-related genes were detected for verification.

[0050] 3. Detection of the Effect of Vanillyl Alcohol on Energy Metabolism of HepG2 Cells

[0051] In the OA / PA group and OA / PA+VA group, mitochondria were stained with mitochondrial fluorescent staining reagent, the amount of cellular mtDNA was quantified, and the changes in ATP content were detected using an ATP detection kit (Shanghai Beyotime Biotechnology Co., Ltd.).

[0052] 4. Detection of the Effect of Vanillyl Alcohol on Oxidative Stress in HepG2 Cells

[0053] The OA / PA group and the OA / PA+VA group used glutathione detection kit (Nanjing Jiancheng), SOD detection kit, and reactive oxygen species to detect changes in intracellular oxidative indicators such as GSH, SOD, CAT, and ROS.

[0054] (2) In vivo experiments are as follows:

[0055] 5. Detecting the Effect of Vanillyl Alcohol on High-Fat Diet-Induced Obesity

[0056] During the in vivo experiment, the body weight of the four groups of mice was recorded weekly, and body fat percentage was measured using MRI, and fat distribution was examined using CT. After the feeding period, adipose tissue was collected, photographed, and weighed to investigate the effects of vanillyl alcohol on high-fat diet-induced obesity.

[0057] 6. Detecting the Effect of Vanillyl Alcohol on Fatty Liver in Mice Fed a High-Fat Diet

[0058] After the feeding experiment, liver tissues were collected, photographed and weighed, and H&E, Oil Red O staining, TG detection and other experiments were performed to explore the effect of vanillin on fatty liver induced by high-fat diet.

[0059] 7. Detection of the Effect of Vanillyl Alcohol on Glucose Metabolism in Mice Fed a High-Fat Diet

[0060] At week 8 of the experiment, mice fasted for 16 hours, had their tail vein blood drawn for fasting blood glucose, and were then intraperitoneally injected with glucose solution (2g / kg). Blood glucose was measured at 15, 30, 60, 90, and 120 minutes after injection. At week 9 of the experiment, mice fasted for 4 hours, had their tail vein blood drawn for fasting blood glucose, and were intraperitoneally injected with insulin (0.75U / kg). Blood glucose was measured at 15, 30, 60, 90, and 120 minutes after injection.

[0061] The experimental results show that:

[0062] 1. Vanillyl alcohol has no significant effect on the activity of HepG2 cells

[0063] To investigate the effect of vanillin on cell viability, cells were treated with vanillin at different concentrations (0, 25 μM, 50 μM, 75 μM and 100 μM). It was found that vanillin had no toxic effect on HepG2 cells within 100 μM (results as shown in Figure 1 shown).

[0064] 2. Vanillyl alcohol alleviates lipid metabolism disorders in HepG2 cells

[0065] 50-100 μM vanillyl alcohol can reduce the triglyceride level in HepG2 cells, and the effect is more significant when treated with 75 μM (results are shown in Figure 2 Therefore, 75 μM vanillyl alcohol was used to continue the subsequent in vitro lipid metabolism study. Oil red O staining also showed that vanillyl alcohol can reduce the accumulation of intracellular lipid droplets (results as shown in Figure 3 The expression of lipid metabolism-related genes in HepG2 cells was quantified. Figure 4 As shown in the results, vanillyl alcohol can inhibit the expression of lipid synthesis genes: ACC1 and FASN, and promote the expression of lipid decomposition and lipid transport genes: PPARα and PGC1α. These results indicate that vanillyl alcohol can alleviate lipid metabolism disorders in HepG2 cells.

[0066] 3. Effects of vanillyl alcohol on energy metabolism in HepG2 cells

[0067] Mitochondria are responsible for lipid metabolism and are therefore widely considered to be important players in the pathology and progression of steatosis. Mitochondrial dysfunction is associated with energy metabolism disorders. Vanillyl alcohol can significantly increase the number of mitochondria in HepG2 cells ( Figure 5 ), mtDNA content ( Figure 6 ), and ATP content ( Figure 7 ), the results showed that vanillyl alcohol can regulate intracellular energy metabolism.

[0068] 4. Effects of vanillyl alcohol on oxidative stress in HepG2 cells

[0069] Oxidative stress is a key factor in the formation of fatty liver. Reactive oxygen species (ROS) disrupt redox homeostasis by inducing oxidative stress, leading to lipid peroxidation and damaging the enzyme antioxidant system, thereby amplifying the effects of oxidative stress. After vanillin treatment of HepG2 cells, ROS and MDA levels decreased ( Figure 8 、 Figure 9 ), the levels of antioxidant enzymes such as GSH, CAT, and SOD increased significantly ( Figure 10 ), the above results indicate that vanillyl alcohol can alleviate high-fat-induced oxidative stress.

[0070] 5. Vanillyl alcohol alleviates obesity induced by high-fat diet

[0071] The experiment used 24 six-week-old male C57BL / 6J mice and randomly divided them into four groups, with 6 mice in each group: CON, HFD, HFD+VA-L, and HFD+VA-H. Vanillyl alcohol was injected intraperitoneally into the mice twice a week for 12 weeks. The experiment was approved by the Animal Experiment Ethics Committee of Guangxi University with the ethics number GXU-2023-0259. The study found that unlike the HFD group, which had a rapid weight gain, VA was able to significantly slow down the increase in weight and fat rate caused by a high-fat diet and increase the lean meat rate (results as shown in the figure). Figure 11 In addition, whole-body CT scans of mice revealed increased body fat in the HFD mice, while the fat content in the HFD+VA-L and HFD+VA-H groups was significantly less than that in the HFD group (results shown in Figure 12 After the mice were killed, the epididymal fat and subcutaneous fat of the mice were collected. Compared with CON, the weight of epididymal and subcutaneous fat in the HFD group increased significantly, while the VA treatment group could significantly reduce the increase in epididymal and subcutaneous fat weight, and the ratio to body weight also decreased significantly (the results are shown in Figure 13 The above results indicate that vanillyl alcohol can alleviate fat deposition in mice induced by a high-fat diet.

[0072] 6. Vanillyl alcohol alleviates high-fat diet-induced liver fat deposition

[0073] After the mice were killed, the liver tissues were collected (the results were as follows Figure 14 As shown), liver TG content and oil red O staining were performed. The HFD group had obvious damage and lipid accumulation, while vanillin could alleviate liver damage and lipid accumulation (the results are shown in Figure 15 The results showed that vanillyl alcohol can alleviate high-fat-induced fatty liver.

[0074] 8. Vanillyl alcohol alleviates the glucose metabolism disorder induced by high-fat diet

[0075] To further evaluate the glucose and insulin levels of mice under different treatment conditions, GTT and ITT tests were performed at week 8 and 9 of treatment. Figure 16 As shown in the figure, the HFD group mice showed decreased glucose tolerance after glucose injection. The VA treatment group significantly reduced the blood sugar level after glucose injection and promoted the return of blood sugar to normal levels compared with the HFD group. Figure 17 As shown in the results, after insulin injection, the blood glucose levels of mice in the HFD group decreased slowly, indicating insulin resistance. However, the blood glucose levels of the VA-treated group decreased significantly less than those in the HFD group, indicating that adding VA to the diet can improve HFD-induced insulin resistance. These results suggest that vanillin can alleviate the glucose metabolism disorders caused by high fat intake.

[0076] In summary, the test results in the embodiments of the present invention show from both in vitro and in vivo experiments that:

[0077] Vanillyl alcohol has no significant effect on liver cell activity within 75uM and has no obvious toxic side effects on liver cells, and has prospects for drug application.

[0078] In in vitro experiments, vanillyl alcohol can reduce TG levels and lipid droplet accumulation in human liver cancer cells HepG2; vanillyl alcohol can increase the number of mitochondria and ATP levels in human liver cancer cells HepG2 cells to promote liver cell energy metabolism; and alleviate oxidative stress by reducing ROS and MDA levels in human liver cancer cells HepG2 and increasing the content of GSH, SOD, and CAT.

[0079] In vivo studies, MRI and CT scans of mice revealed that vanillyl alcohol significantly slowed the increase in body weight and fat mass induced by a high-fat diet and increased lean meat percentage. Vanillyl alcohol also reduced triglyceride accumulation in the livers of mice, indicating that vanillyl alcohol can improve fat deposition induced by a high-fat diet. Testing of glucose and insulin levels in mice under different treatment conditions revealed that vanillyl alcohol enhanced glucose tolerance and improved insulin resistance in mice induced by a high-fat diet, suggesting that vanillyl alcohol can alleviate the glucose metabolism disorders induced by a high-fat diet. These results demonstrate that vanillyl alcohol can improve glucose and lipid metabolism disorders induced by a high-fat diet.

[0080] The results of in vitro and in vivo tests in the examples of the present invention show that vanillyl alcohol has the potential to be used in the preparation of drugs for preventing and treating fatty liver, obesity or diabetes.

[0081] The prevention and treatment include one or more of prevention, alleviation or treatment.

[0082] The fatty liver is metabolism-related fatty liver disease.

[0083] The diabetes is type 2 diabetes.

[0084] The prepared medicine for preventing and treating fatty liver, obesity or diabetes is an injectable preparation or an oral medicine.

[0085] The injection preparation drug is one of an injection liquid preparation, a freeze-dried powder injection, an emulsion preparation, a sustained-release preparation or a microcapsule preparation.

[0086] The injection preparation further contains pharmaceutically acceptable excipients and / or carriers. The excipients and / or carriers are one or more of saline, sterile water, Ringer's solution, buffered saline, glucose solution, maltodextrin solution, glycerol, ethanol, lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0087] As a preferred embodiment, the amount of the vanillyl alcohol used is 200 mg / kg-400 mg / kg. More preferably, the amount of the vanillyl alcohol used is 200 mg / kg.

[0088] Compared with the prior art, the present invention has the following beneficial effects:

[0089] The present invention found that vanillyl alcohol can alleviate obesity induced by a high-fat diet and reduce the accumulation of triglycerides in the liver of mice fed a high-fat diet. Vanillyl alcohol improved glucose tolerance and insulin sensitivity in mice induced by a high-fat diet. In summary, vanillyl alcohol can improve disorders of glucose and lipid metabolism and alleviate the occurrence of fatty liver and diabetes. Therefore, it is confirmed that vanillyl alcohol can be used in the preparation of drugs for the prevention and treatment of fatty liver, obesity or diabetes; and vanillyl alcohol does not produce toxic side effects such as changes in cell activity. Therefore, a low-toxicity natural small molecule drug - vanillyl alcohol - is provided for the effective prevention or treatment of fatty liver, obesity or diabetes. Compared with the high-cost fat-reducing drugs currently available on the market, vanillyl alcohol has better natural biological activity, a wide source, low price, and is extremely easy to obtain, with broad application prospects.

[0090] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. Vanillyl alcohol is used in the preparation of drugs for preventing and treating fatty liver, obesity or diabetes.

2. Use of the vanillyl alcohol according to claim 1 in the preparation of a medicament for preventing and treating fatty liver, obesity or diabetes, characterized in that: The control includes one or more of prevention, alleviation or treatment.

3. Use of the vanillyl alcohol according to claim 1 in the preparation of a medicament for preventing and treating fatty liver, obesity or diabetes, characterized in that: The fatty liver is metabolism-related fatty liver disease.

4. Use of the vanillyl alcohol according to claim 1 in the preparation of a drug for preventing and treating fatty liver, obesity or diabetes, characterized in that: The diabetes is type 2 diabetes.

5. Use of the vanillyl alcohol according to claim 1 in the preparation of a medicament for preventing and treating fatty liver, obesity or diabetes, characterized in that: The prepared medicine for preventing and treating fatty liver, obesity or diabetes is an injectable preparation or an oral medicine.

6. Use of the vanillyl alcohol according to claim 5 in the preparation of a drug for preventing and treating fatty liver, obesity or diabetes, characterized in that: The injection preparation drug is one of an injection liquid preparation, a freeze-dried powder injection, an emulsion preparation, a sustained-release preparation or a microcapsule preparation.

7. Use of the vanillyl alcohol according to claim 5 in the preparation of a drug for preventing and treating fatty liver, obesity or diabetes, characterized in that: The injection preparation also contains pharmaceutically acceptable excipients and / or carriers.

8. Use of the vanillyl alcohol according to claim 7 in the preparation of a medicament for preventing and treating fatty liver, obesity or diabetes, characterized in that: The auxiliary materials and / or carriers are one or more of saline, sterile water, Ringer's solution, buffered saline, glucose solution, maltodextrin solution, glycerol, ethanol, lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.

9. Use of the vanillyl alcohol according to claim 1 in preparing a drug for preventing and treating fatty liver, obesity or diabetes, characterized in that: The dosage of the vanillyl alcohol is 200mg / kg-400mg / kg.

10. Use of the vanillyl alcohol according to claim 1 in preparing a drug for preventing and treating fatty liver, obesity or diabetes, characterized in that: The dosage of the vanillyl alcohol is 200 mg / kg.

Images